“The results show that the majority of U.S. consumers perceive cannabis (as CBD, hemp, marijuana, and THC) as having medical uses and view the potential for abuse of cannabis as less than for commonly prescribed medications and alcohol.”
“This study provides evidence that the types of cannabis available in recreational and medical cannabis dispensaries might hold promise as an alternative treatment for PTSD. … This study’s primary outcome supports the theory that cannabis should be [tested in clinical trials] as a potential therapeutic for PTSD.”
“Most older adults in the sample initiated [their] cannabis use after the age of 60 years and used it primarily for medical purposes to treat pain, sleep disturbance, anxiety, and/or depression.”
“Using a large dataset of medical cannabis users self-medicating for symptoms of OCD, we found that for the vast majority of cannabis use sessions individuals reported reductions in intrusions, compulsions, and anxiety.”
The State Health Department Secretary publicly announced on Thursday that patients diagnosed with anxiety disorders and/or Tourette’s syndrome will be eligible to receive recommendations to legally access medical cannabis products. The new rules take effect on July 20.
Inhaled cannabis is effective and well-tolerated in patients with Tourette’s Syndrome, according to clinical data published online ahead of print in the Journal of Neuropsychiatry and Clinical Neuroscience. They concluded: “Overall, these study participants experienced substantial improvements in their symptoms. This is particularly striking given that almost all participants had failed at least one anti-tic medication trial.
[Editor’s note: This post is excerpted from this week’s forthcoming NORML weekly media advisory. To…